Interaction management
Bactrim interactions: methotrexate and warfarin need different answers
A generic instruction to monitor can hide an important difference. The Bactrim interaction table advises avoiding concurrent methotrexate, while warfarin requires reassessment of coagulation. Read the named medicine rather than reusing one response for both.
Sources checked October 12, 2026. Independent educational content, not NABP exam questions or individual treatment advice.
Read the methotrexate instruction as written
The current Bactrim interaction table says to avoid concurrent methotrexate. Sulfonamides can displace methotrexate from protein binding and compete with its renal transport, increasing free methotrexate concentrations.
A low weekly methotrexate dose does not make the interaction vanish. Reconcile the actual medicine, indication, dose and timing. Do not change the weekly schedule into daily dosing or assume an antibiotic course is too short to matter.
Give warfarin a coagulation plan
Bactrim can prolong prothrombin time in patients receiving warfarin, and the label calls for reassessment of coagulation time. An INR follow-up and clinical anticoagulation review are relevant, with attention to bleeding symptoms and the actual treatment course.
Do not invent a fixed percentage warfarin reduction from this label alone. Patient response, baseline INR, infection and the antibiotic duration matter. The exam distinction is between identifying the interaction and pretending the same dose adjustment fits everyone.
Do not let one laboratory result clear both combinations
An INR addresses anticoagulation; it does not exclude methotrexate toxicity. A methotrexate assay can also be affected by trimethoprim with certain assay methods, as the label notes. Laboratory results need their test method and clinical context.
Medication reconciliation should include other toxicity risks and the reason the antimicrobial is being used. Resolving one interaction does not make the whole prescription safe.
Keep the response specific and actionable
For methotrexate, the proposed combination needs prescriber review and an alternative plan because the label says avoid concurrent use. For warfarin, the plan needs coagulation reassessment and clinical monitoring rather than reassurance based on a previously stable INR.
A real antibiotic choice depends on infection evidence. This case does not authorize stopping needed chronic medicines or picking a replacement antibiotic from memory. It tests whether the two interaction instructions are being kept distinct.
A worked case
A patient takes weekly methotrexate and warfarin with a stable INR. Bactrim is proposed, and a draft says only to repeat the INR next month. Identify what that plan misses.
- Concurrent methotrexate is an avoid-use interaction in the Bactrim table.
- A previously stable INR does not prevent a new warfarin interaction.
- The antibiotic and chronic regimen require prompt prescriber review with a suitable coagulation follow-up.
Answer: One distant INR check cannot address both risks. Keep the methotrexate avoidance instruction separate from the warfarin monitoring plan.
Try it before reading the answer
Write the key fact, decision and safety check first. These are original practice exercises, not recalled exam items.
1. Does a stable INR exclude the Bactrim-warfarin interaction?
No.
2. Does INR testing exclude methotrexate toxicity?
No.
3. What does the Bactrim table say about concurrent methotrexate?
Avoid concurrent use.
Continue learning
Put the topic into a study planSources and scope
Source dates and limits matter. Follow the current official source for clinical or regulatory decisions. Examples are simplified teaching cases, not prescribing, diagnostic or compounding instructions. Check the full current guidance and individual clinical context.